上海沿浦(605128.SH)IPO定價23.31元/股 網上申購日為9月3日
格隆匯8月12日丨上海沿浦(605128.SH)披露首次公開發行股票推遲發行公告,該次發行採用直接定價方式,全部股份通過網上向社會公眾投資者發行,不進行網下詢價和配售。發行價格確定為23.31元/股,申購日為2020年9月3日,繳款日為2020年9月7日。
發行價格23.31元/股對應的市盈率為22.9927倍,高於中證指數有限公司發佈的行業最近一個月平均靜態市盈率(截止2020年8月10日)。
該次公開發行股票總數量2000萬股,發行後流通股佔公司發行後總股本的25.00%,網上發行2000萬股,佔該次發行總量的100%。該次發行股份全部為新股,不進行老股轉讓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.